With mutation, expression, and epigenetic features from hundreds of medulloblastoma tumors, researchers characterized key features of brain tumor subtypes.
Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.
Suspicious variants were uncovered through analyses of pediatric cancer survivors from the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study.
The lab-developed test will use Thermo Fisher Scientific's Ion sequencing platform and will be applicable to most childhood cancers.
Researchers hope to identify exosomal biomarkers that can predict or detect cancer recurrence and metastasis at its earliest stages.
The study showed that targeted sequencing was feasible, identified many clinically relevant alterations, and directed effective targeted therapy in several cases.
Under the PIPseq program, Columbia University researchers sequenced the exome, transcriptome, or a gene panel in tumors of 101 high-risk pediatric cancer patients.
The researchers found that 80 percent of pediatric posterior fossa ependymomas have decreased levels of H3K27me3 histone modifications.
NantHealth, CHOP, and their collaborators intend to release genomic, transcriptomic, and proteomic data from 1,600 patients in the next six months
BC Cancer Agency researcher Marco Marra presented preliminary lessons from a cancer genome- and transcriptome-based trial underway in the province.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.